Educational reference, not medical advice. This page summarizes information from published research and regulatory filings for educational purposes. It is not a recommendation to use any compound and should not replace guidance from a licensed healthcare provider. Most peptides discussed here are not approved for the uses described.
What it is
P21, also written P021 in the primary literature, is a small peptidergic compound modeled on a four-amino-acid active region of ciliary neurotrophic factor (CNTF). The Iqbal lab designed the molecule by identifying the smallest CNTF fragment that retained the cytokine's neurogenic activity, then attaching adamantane and other moieties to confer enzymatic stability, blood-brain barrier penetration, and oral bioavailability. The result is a compound that is small enough to be classified as a peptidomimetic rather than a conventional peptide drug.
P21 has been studied extensively as a research tool for Alzheimer's disease, where the working hypothesis is that loss of neurotrophic support contributes to cognitive decline and that a stable, brain-penetrant CNTF mimetic might rescue synaptic and neurogenic deficits.
History
The compound was developed at the New York State Institute for Basic Research in Developmental Disabilities under Khalid Iqbal, whose group had spent decades on the biochemistry of Alzheimer's disease pathology. The early characterization papers by Blanchard, Bolognin, and Kazim (between 2010 and 2014) described disease-modifying effects of oral P21 in two well-established rodent Alzheimer models: the triple-transgenic 3xTg-AD mouse and aged wild-type rats with naturally occurring cognitive decline.
The 2014 Kazim et al. paper in Neurobiology of Disease is the most cited primary characterization. The 2016 review by Kazim and Iqbal places P21 in the broader context of small-molecule neurotrophic mimetics being explored for Alzheimer's disease.
P21 has not been licensed to a clinical-stage developer, and there is no registered Phase I trial in humans.
Regulatory status
P21 has no approved medical use. It has not been the subject of a published Phase I trial registered with the FDA or EMA. It is sold only through research-chemical suppliers, with not-for-human-use labeling.
How researchers describe its action
The published mechanism account describes P21 as a CNTF-mimicking neurotrophic agent that engages downstream pathways shared by CNTF, leukemia inhibitory factor, and related cytokines, but without the systemic adverse effects historically associated with recombinant CNTF. The key effects characterized in rodent studies:
- Adult neurogenesis. P21 increases hippocampal neurogenesis in aged rodents and in the 3xTg-AD model.
- Synaptic plasticity. Long-term potentiation and dendritic spine density are restored toward control levels after chronic oral P21.
- Cognitive rescue. Performance in spatial memory tasks (Morris water maze and contextual fear conditioning) is improved in treated AD-model mice.
- Disease-modifying signature. The 2014 Kazim et al. paper reported reductions in tau hyperphosphorylation and amyloid burden in 3xTg-AD mice after chronic oral treatment.
All these effects are preclinical and have been characterized primarily by the Iqbal lab and immediate collaborators.
Half-life and dosing intervals
Pharmacokinetic data for P21 are limited and published primarily in the rodent literature. Plasma half-life is on the order of 2 to 4 hours in rats after oral administration, with measurable brain concentrations supporting once-daily oral dosing in the published protocols.
In rodent studies, oral P21 doses on the order of 60 nmol/g of diet (delivered ad libitum in chow) or 1 to 5 mg/kg by gavage have been used. There is no established human dose. The doses commonly described in informal observational use have no controlled-trial basis.
Reconstitution example
Research-grade P21 is sold as a lyophilized powder, typically in 10 mg or 20 mg vials. The compound is small and lipophilic; suppliers usually recommend reconstitution in DMSO or ethanol for cell-culture stocks. For subcutaneous research administration, a 10 mg vial reconstituted with 2 mL of bacteriostatic water (with co-solvent if needed for solubility) yields 5 mg/mL.
Vial's calculator handles the mass-to-volume conversion when you enter the vial mass and water volume. Because P21 is poorly water-soluble, supplier-specific vehicle guidance matters more than for typical peptides.
What to know
- Strictly preclinical. All efficacy data is from cell culture and rodent studies, almost entirely from one laboratory and its immediate collaborators.
- Oral bioavailability. Unlike most peptides, P21 was deliberately designed for oral administration; the primary research route in published studies is oral chow or gavage.
- No safety database in humans. Rodent studies have not flagged major toxicity at the doses used, but no Phase I human trial exists.
- Storage. Lyophilized P21 is stable refrigerated and most stable frozen. Stock solutions in DMSO or ethanol should be aliquoted and frozen to avoid repeated freeze-thaw cycles.
- Peptidomimetic, not a classical peptide. P21 includes non-natural protecting groups that make it more drug-like than peptide-like in behavior, which is part of why the program emphasized oral dosing.
Sources
- 1.Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K (2014). Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiology of Disease.
- 2.Bolognin S, Buffelli M, Puoliväli J, Iqbal K (2014). Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiology of Aging.
- 3.Kazim SF, Iqbal K (2016). Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Molecular Neurodegeneration.
- 4.Blanchard J, Wanka L, Tung YC, Cárdenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-Iqbal I (2010). Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathologica.